Silo Pharma Seeks Shareholder Approval for Massive 37.5x Increase in Authorized Common Stock

summarizeSummary

Silo Pharma is seeking shareholder approval to increase its authorized common stock from 6.67 million to 250 million shares, enabling significant future capital raises for acquisitions and operations.

check_boxKey Events

• Proposed Authorized Share Increase

  Shareholders will vote on increasing authorized common stock from 6,666,667 to 250,000,000 shares.

• Significant Potential Dilution

  If all authorized shares were issued, dilution would be over 22,000% relative to current outstanding shares.

• Purpose for Capital Raising

  The company intends to use the additional shares to raise equity capital for acquisitions of in vitro fertilization clinics and general corporate purposes to reach cash flow breakeven.

• Annual Meeting Scheduled

  The proposals will be voted on at the 2026 Annual Meeting of Shareholders on August 14, 2026.

auto_awesomeAnalysis

Silo Pharma is asking shareholders to approve an amendment to its Articles of Incorporation to increase the number of authorized common shares from 6,666,667 to 250,000,000. This represents a potential increase of over 22,000% in shares relative to the current outstanding count of 1,128,610. The company states this is necessary to raise equity capital for business objectives, including acquisitions of in vitro fertilization clinics to reach cash flow breakeven. This authorization, if approved, provides the company with significant flexibility for future capital raises, but also introduces a substantial overhang of potential dilution for existing shareholders.